TOT BIOPHARM INTERNA

1875
End-of-day quote. End-of-day quote  - 11/29
4.01HKD -3.61%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 2 2291 976
Entreprise Value (EV)1 2 2291 976
P/E ratio --
Yield --
Capitalization / Revenue 99,1x16,7x
EV / Revenue 99,1x16,7x
EV / EBITDA -8,69x-7,08x
Price to Book 3,63x3,91x
Nbr of stocks (in thousands) 600 467601 529
Reference price (CNY) 3,713,28
Announcement Date 03/23/2021-
Previous period Next period
1 HKD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 22,5118
EBITDA1 -257-279
Operating profit (EBIT)1 -289-207
Operating Margin -1 284%-176%
Pre-Tax Profit (EBT) --
Net income --
Net margin --
EPS --
Dividend per Share --
Announcement Date 03/23/2021-
Previous period Next period
1 CNY in Million
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt --
Net Cash position --
Leverage (Debt / EBITDA) --
Free Cash Flow1 -284-338
ROE (Net Profit / Equities) -40,1%-22,0%
Shareholders' equity --
ROA (Net Profit / Asset) -34,8%-12,0%
Assets --
Book Value Per Share2 1,020,84
Cash Flow per Share2 -0,46-0,16
Capex1 20,5156
Capex / Sales 91,1%132%
Announcement Date 03/23/2021-
Previous period Next period
1 CNY in Million
2 CNY
Financial Ratios
Size 2021e 2022e
Capitalization 1 976 M CNY -
Valuation 2021e 2022e
P/E ratio (Price / EPS) - -
Capitalization / Revenue 16,7x 7,42x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 3,91x 3,61x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) -176% -71,9%
Operating Leverage (Delta EBIT / Delta Sales) 0,07x 0,06x
Net Margin (Net Profit / Revenue) 0 0
ROA (Net Profit / Asset) -12,0% 4,00%
ROE (Net Profit / Equities) -22,0% 8,00%
Rate of Dividend - -
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   132% 41,3%
Cash Flow / Sales -81,6% 31,6%
Capital Intensity (Assets / Sales) -0 0
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend